This is the last part of my discussion with Dr. Matthew Horton, a pathologist with a special training and a great expertise in lung pathology who works here in Seattle at a company called CellNetix.

We focus in this last one on the increasing focus on molecular markers in making clinical decisions and how this is changing the relationship of pathologists with oncologists, as well as the need for pathologists to provide this information in a timely way.

dr-horton-pt-3-transition-to-molecular-pathology-audio-podcast

dr-horton-pt-3-transition-to-molecular-pathology-transcript

dr-horton-pt-3-transition-to-molecular-pathology-figures

Next, we'll turn to coverage of imaging issues in cancer management.